Danicopan for Paroxysmal Nocturnal Hemoglobinuria: Dosage, Side Effects, Administration, and Pharmacology

Overview:

A drug called Danicopan is used to treat paroxysmal nocturnal hemoglobinuria (PNH). It is a complement inhibitor that binds to factor D reversibly to stop hemolysis and complement C3 protein deposition on red blood cells caused by alternative pathways.

In January 2024, Danicopan received approval for medicinal usage in Japan, and in March 2024, it received approval in the US (United States).

Drug Group: Complement factor D inhibitor.

Danicopan is a member of a relatively recent class of medications that target the immune response's complement system. In particular, it suppresses factor D, a protein essential to the activation cascade that causes EVH (extravascular hemolysis) in PNH patients.

Available Doses: 50mg (milligrams), 100 mg, and 200 mg tablets.

Dosage Form: Oral tablets.

For Patients:

What Is Paroxysmal Nocturnal Hemoglobinuria?

PNH is a rare and severe blood illness that is characterized by intravascular hemolysis (IVH), or the destruction of red blood cells within blood arteries, and activation of platelets and white blood cells that can lead to thrombosis (blood clots), which can cause organ damage and perhaps early death. About 10 to 20 percent of PNH patients on C5 inhibitor therapy develop clinically severe EVH (extravascular hemolysis), which can lead to persistent anemia (reduced red blood cell count) symptoms and necessitate blood transfusions. The root cause is the synthesis of two particular proteins (CD55 and CD59) on the surface of red blood cells that are interfered with by a genetic mutation in a blood cell’s stem cell. Normally, these proteins shield red blood cells from immune system assaults.

• Hemolysis Forms: PNH can induce two primary forms of hemolysis. Red blood cells are damaged inside blood arteries when there is intravascular hemolysis (IVH).

• Extravascular Hemolysis (EVH): This occurs mostly in the liver and spleen, where red blood cells are broken down outside of the circulation.

How Does Danicopan Work?

Danicopan focuses on the core reason why PNH patients have EVH. Here is how it works:

1. Complement System: Normally, the immune system's complement system aids in the defense against infections. It becomes hyperactive in PNH and adds to EVH.

2. Factor D Inhibition: Danicopan functions as an inhibitor of complement factor D. A protein called factor D is essential for opening a particular route in the complement system that causes EVH. Danicopan works by blocking factor D, which helps to:

• Lessen the loss of red blood cells outside of the circulation.

• Boost the survival of red blood cells overall.

What Is the Dosage of Danicopan?

• Danicopan is prescribed at a dosage of 300 mg, given twice a day.

• Danicopan is used as an adjuvant treatment in addition to inhibitors such as Ravulizumab or Eculizumab.

• Doses between 100 mg and 200 mg three times a day (TID) have been studied in clinical studies. Ongoing phase 3 trials will, however, determine the ideal dose for long-term usage.

How Effective Is Danicopan?

Danicopan's phase two clinical studies have produced encouraging results:

• Better Hemoglobin Levels: In PNH patients whose hemoglobin levels were not sufficiently managed by Eculizumab alone, adding Danicopan to Eculizumab therapy showed a substantial rise in hemoglobin levels.

• Lower Transfusion Needs: Compared to patients on Eculizumab alone, patients receiving Danicopan plus Eculizumab needed fewer blood transfusions.

• Improvement in Tiredness: Research indicates that individuals on Danicopan saw a decrease in tiredness scores when compared to those on Eculizumab alone.

Phase three studies are now being conducted to verify the long-term safety and effectiveness of Danicopan in combination with Ravulizumab or Eculizumab. The results of these trials will showcase a clearer picture of Danicopan's efficacy.

What Are the Things to Inform the Doctor Before Taking the Drug?

• Medical History: Provide whole medical history, taking into account any underlying diseases or prescribed drugs.

• Allergies: Let the doctor know about any allergies, particularly to any drugs.

• Current Medications: Please include all the medications used, including over-the-counter, prescription, and herbal supplements. This facilitates the identification of possible Danicopan interactions.

• Pregnancy or Breastfeeding: Talk about whether intending to get pregnant, are currently nursing, or are pregnant. Investigations are ongoing to determine if Danicopan is safe to use while pregnant or nursing.

• Lab Test Findings: Please share the findings of any recent tests one may have had, especially if they concern blood cell counts or PNH.

How Is Danicopan Administered?

Danicopan is meant to be taken orally, as it is intended for oral administration.

• Danicopan is sold as tablets with varying dosages (50mg, 100mg, 150mg, 200mg).

• The doctor will decide on the precise dose schedule (once daily, twice daily) depending on the patient’s unique needs and response to the medication.

• Three oral doses of 150 to 200 mg of Danicopan are typically given daily.

What Are the Side Effects of Danicopan?

The following are the main possible negative effects of using Danicopan to treat paroxysmal nocturnal hemoglobinuria (PNH):

• Side effects related to the stomach:

  • Nausea.

  • Diarrhea.

  • Abdominal pain.

• Respiratory side effects:

  • Nasopharyngitis (common cold).

  • Upper respiratory tract infections.

• Headache.

• Fatigue.

• Elevated liver enzymes.

• Hypersensitivity reactions:

  • Rash.

  • Urticaria (hives).

  • Angioedema (swelling of the skin and tissue).

It is important to note that not all patients will experience these side effects, and the severity can vary. Additionally, some side effects may be more common when Danicopan is used in combination with other PNH medications, such as Eculizumab or Ravulizumab.

Dietary Considerations:

There are no particular dietary restrictions when using Danicopan; patients should continue to follow recommendations for a balanced, healthy diet for both their general well-being and the management of PNH. Danicopan can be taken with or without meals.

Missed Dose:

The patient should take the missing dosage of Danicopan as soon as they recall it if they forget to take it. On the other hand, the patient should proceed with the usual dosage plan and forgo the missed dose if the next scheduled dose is almost here. Patients are not recommended to take two doses to make up for a missing one.

Overdose:

Patients who overdose should get medical help right away or get in touch with a poison control center. Danicopan overdose has no known particular remedy; instead, supportive care and condition monitoring are the mainstays of treatment.

Storage:

• It is recommended to store Danicopan at room temperature, normally between 20 and 25 degrees Celsius (C) (68 and 77 degrees Fahrenheit).

• The drug has to be stored out of direct sunlight, heat, and moisture in its original container.

• Patients are responsible for making sure that the kids cannot get the medicine.

• It is important to verify the expiration date of the drug and avoid using it after that time.

For Doctors:

Indication:

Danicopan is prescribed for people with paroxysmal nocturnal hemoglobinuria (PNH) who have extravascular hemolysis that is clinically substantial in addition to C5 inhibitors (Eculizumab or Ravulizumab).

Dose:

The recommended dose of Danicopan is 100 to 200 mg, taken orally twice or thrice daily, depending on the patient’s unique needs.

Dosing Considerations:

It is best to take Danicopan with meals.

1. When commencing Danicopan, patients should keep taking their usual dosage of the C5 inhibitor (Ravulizumab or Eculizumab).

2. Age, sex, ethnicity, or renal function do not need to change the dosage of Danicopan.

3. A lower dosage of Danicopan may be necessary for patients with moderate to severe hepatic impairment.

4. A healthcare professional skilled in PNH management should oversee the start and continuation of Danicopan treatment.

What Are the Pharmacological Aspects of Danicopan?

1. Pharmacodynamics: A crucial enzyme in the alternative complement pathway, complement factor D, is selectively and potently inhibited by Danicopan. Danicopan lessens the activation of the alternative complement pathway, which is crucial in the breakdown of red blood cells in paroxysmal nocturnal hemoglobinuria (PNH), by blocking factor D. Extravascular hemolysis is reduced as a result of this blockage of the alternative complement pathway, and this is one of the main causes of anemia in PNH patients.

2. Mechanism: The body constantly activates the alternative complement pathway at a low level, and factor D is an essential enzyme that propels this activation. By attaching itself to factor D and inhibiting it, Danicopan stops the alternative route from being activated, which would have destroyed PNH red blood cells. The C5 inhibitors, Ravulizumab and Eculizumab, block the terminal portion of the complement cascade; this mode of action is different from that of Danicopan.

3. Pharmacokinetics:

• When taken orally, Danicopan is quickly absorbed, taking one to two hours to reach its maximum concentration (Tmax).

• Danicopan's bioavailability is between 50 and 60 percent.

• Danicopan undergoes enterohepatic recirculation and is mostly metabolized by CYP3A4 (cytochrome P 3A4).

• Danicopan has an elimination half-life of 12 to 15 hours, which permits a twice-daily dosage.

• The exposure to Danicopan is not substantially influenced by age, gender, race, or mild to severe renal impairment.

• Due to increased drug exposure, patients with moderate to severe hepatic impairment could need a lower dosage of Danicopan.

Toxicity:

• Danicopan’s adverse responses that were most often observed in clinical trials included headache, tiredness, diarrhea, and nausea.

• In the clinical studies, no dosage-limiting toxicities were found.

• A limited number of individuals experienced serious adverse effects. However, they were not thought to be connected to the Danicopan therapy.

• Based on the clinical data available, it does not seem like there are any substantial toxicity issues with Danicopan.

Clinical Studies:

• In patients with PNH, the safety, and effectiveness of Danicopan as a supplement to C5 inhibitors was assessed in a phase 3 randomized, placebo-controlled study.

• Comparing Danicopan to placebo in this research, the drug considerably raised hemoglobin levels and decreased the need for blood transfusions.

• Danicopan-treated patients also showed improvements in quality of life and extravascular hemolysis metrics.

• Danicopan's safety profile included a low incidence of major adverse events and was usually well-tolerated.

What Are the Contraindications of Danicopan?

• Patients who have experienced severe or potentially fatal allergic responses to any of the components in Danicopan should not use this medication.

• Danicopan should not be used in patients with uncontrolled hypertension as it might make their blood pressure even higher.

• Because of the risk of increased drug exposure and toxicity, it is not advised for patients with severe hepatic impairment (Child-Pugh Class C) to take Danicopan.

• In conclusion, clinical trials have shown that Danicopan has a good safety profile. The primary contraindications are associated with hypersensitivity responses and uncontrolled hypertension. It is advised to monitor closely, particularly in individuals who have liver impairment.

Warnings and Precautions:

• Hypertension: Danicopan has the potential to elevate blood pressure. Regular blood pressure checks are necessary, and antihypertensive medication should be started or stopped as necessary.

• Events Associated With Infusion: Individuals using Danicopan concurrently with Eculizumab or Ravulizumab, two C5 inhibitors, may experience events related to infusion. It is advised that infusion-related responses be monitored and treated appropriately.

• Immunization: Given the potential for infection in PNH patients, immunization against encapsulated bacteria is advised either before or during Danicopan therapy.

• Monitoring: Throughout Danicopan therapy, routine monitoring of liver function, blood counts, and other pertinent indicators is advised.

What Are the Drug Interactions of Danicopan?

• CYP3A4 Inhibitors: Using potent CYP3A4 (Cytochrome P450 3A4) inhibitors concurrently, such as Ketoconazole, Itraconazole, or Ritonavir, may raise Danicopan exposure and require a lowering dosage.

• CYP3A4 Inducers: Using potent CYP3A4 inducers concurrently, such as Rifampicin and St. John's wort, may reduce Danicopan exposure and necessitate dosage modification.

• Other Complement Inhibitors: Danicopan should not be taken with other complement inhibitors since doing so might make infections more likely.

Specific Considerations:

• Hepatic Impairment: Because of increased drug exposure, patients with moderate to severe hepatic impairment (Child-Pugh Class B or C) may need a lower dosage of Danicopan.

• Renal Impairment: Patients with mild to moderate renal impairment do not need to alter their dosage. Patients with severe renal impairment should use caution.

• Pregnancy and Lactation: The use of Danicopan in women who are pregnant or nursing has not been well studied. It is important to carefully weigh the advantages and potential drawbacks.

• Pediatrics: It is unknown if Danicopan is safe and effective for use in young PNH patients. Currently, only adult PNH patients are permitted to utilize Danicopan.

• Elderly: Studies on adult PNH patients, particularly those 65 years of age and older, have been conducted on Danicopan. There were no discernible variations in Danicopan's safety or effectiveness between adult patients who were younger and older. Age alone does not need dose modifications. As with any medicine, older people may require greater observation, especially if they are taking numerous medications or have other medical issues.